Prevalence of human papillomavirus infection and risk of cervical cancer or precancerous lesions in 15 years follow up:a prospective cohort study
10.3760/cma.j.issn.0253-3766.2016.10.017
- VernacularTitle:高危型人乳头瘤病毒感染变化与宫颈癌及癌前病变发病风险的15年前瞻队列随访研究
- Author:
Qian ZHANG
1
;
Shangying HU
;
Ruimei FENG
;
Li DONG
;
Feng CHEN
;
Xun ZHANG
;
Qinjing PAN
;
Junfei MA
;
Shaodong SHI
;
Fanghui ZHAO
;
Youlin QIAO
Author Information
1. 100021,国家癌症中心 中国医学科学院北京协和医学院肿瘤医院流行病学研究室
- Keywords:
Human papillomavirus;
Uterine cervical neoplasms;
Cohort studies;
Incidence risk
- From:
Chinese Journal of Oncology
2016;38(10):792-797
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the 15 years changing trends of prevalence of high risk HPV (HR?HPV) infection and the risks of cervical cancer and precancerous lesions (CIN2+) among a Chinese rural population. Methods The screening cohort with 1 997 women aged 35 to 45 years old was built in 1999 in Xiangyuan County, Shanxi province ( SPOCCS?I) and followed up by cytology and HR?HPV testing in the years of 2005, 2010, and 2014. The changes of HR?HPV prevalence and the risks of cervical precancerous lesions with CIN2+ as the endpoints were analyzed during the past 15 years. Results The detection rates of HPV infection and CIN2+ were 15.7%?22.3% and 1.1%?4.3% for the baseline visit and the other 3 follow?ups, respectively. The cumulative risk of CIN2+ in HR?HPV positive women at baseline was significantly higher than HR?HPV negative women ( P<0.01) during the 15?year follow?up. The risk of CIN2+ in the four?times HPV positive group was 40. 0%, while the group with four?times negative HPV results was 0.6% (Adjusted RR = 55.0, 95% CI: 11.3 to 268.4). Conclusions The prevalence of HR?HPV infection and CIN2+ lesions were high in Xiangyuan county during the 15 years. HR?HPV positivity elevated the risk of CIN2+ compared to women whose HR?HPV test was negative. The risks of CIN2+incidence in 6 years were low among women with negative HR?HPV test. The risk of CIN2+ increased with the numbers of HPV infection events. The screening interval could be extended to 5?6 years.
